Home
About UsCommitted to developing a new generation of CNS medicines that go beyond the current standard of care
Vistagen is developing an innovative pipeline of Central Nervous System (CNS) medications with the potential to establish new standards of care in the treatment of a variety of serious anxiety, depression and other CNS disorders that are disrupting the lives of tens of millions of people in the U.S. and around the world.
Our VisionStriving for a world no longer gripped by anxiety and depression
Vistagen’s core goal is to radically improve mental health and well-being worldwide. In developing safe and effective treatments, we aim to improve mental health care with better outcomes for patients, caregivers, advocates and communities.
25 Million1
Americans suffer from Social Anxiety Disorder
19.4 Million2
Adults in the US had at least one major Depressive Episode
264 Million3
People World-wide suffer from Depression
1. Kantar Health. Nov 2021. National Health and Wellness Survey (NHWS), 2021. [US]. Malvern, PA. | 2. Substance Abuse and Mental Health Services Administration, 2020 | 3. World Health Organization
Pipeline Vistagen Products in Development
For Anxiety Disorders
Fasedienol is a first-in-class, rapid-onset investigational pherine nasal spray designed with potential to treat multiple anxiety disorders without the side effects and safety concerns associated with currently prescribed anti-anxiety products.
For Depression
Itruvone is a rapid-onset investigational pherine nasal spray designed for potential stand-alone treatment for major depressive disorder and other neuropsychiatric indications involving depression.
For Menopausal Hot Flashes, Premenstrual Dysphoric Disorder and Migraine
PH80, an investigational pherine, is a potential treatment for the acute management of vasomotor symptoms (hot flashes) due to menopause, acute management of symptoms of premenstrual dysphoric disorder and acute treatment of migraine.
For Improvement of Cognition
PH15 is an investigational pherine designed as a potential new treatment for many disorders that lead to sleep deprivation and ensuing fatigue and cognitive impairment.
For Appetite-related Disorders
PH284 is an investigational pherine with potential to treat appetite related disorders such as Cachexia (Wasting Syndrome), a serious but under recognized consequence of many chronic diseases and advanced cancer.
For CNS Diseases & Disorders
AV-101 (4-Cl-KYN) is an investigational oral prodrug of 7-Cl-KYNA, a full antagonist of the glycine site of the NMDA receptor, with potential to treat multiple CNS diseases and disorders.
Data as of Dec 4, 2023 | 5:42 PM EST